Home > Insider Trading > Filing (0001209191-21-055273)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
718937	Staar Surgical Co	STAA	Ophthalmic Goods (3851)	953797439

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1488891	Hans-Martin Blickensdoerfer	25651 Atlantic Ocean Drive Lake Forest CA 92630	Sr. Vp, Comm. Ops, China	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2021-09-07	11,522	$157.40	77,200	No	4	S	Direct
Common Stock	Acquisiton	2021-09-07	14,031	$35.98	91,231	No	4	M	Direct
Common Stock	Acquisiton	2021-09-07	15,100	$27.53	106,331	No	4	M	Direct
Common Stock	Disposition	2021-09-07	29,131	$157.40	77,200	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	M	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Common Stock Options	Disposition	2021-09-07	14,031	$0.00	14,031	$35.98
Common Stock	Common Stock Options	Disposition	2021-09-07	15,100	$0.00	15,100	$27.53

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
4,109	2020-03-14	2029-03-13	No	4	M	Direct
16,879	2021-03-20	2030-03-19	No	4	M	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.40 to $157.45, inclusive.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $157.40 to $157.46, inclusive.
The options granted become exercisable as follows: 1/3 on 3/14/2020 and the remaining 2/3 of such options shall become exercisable over the following 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/13/2029.
The options granted become exercisable as follows: 1/3 on 3/20/2021 and the remaining 2/3 of such options shall become exercisable over the next 24 months in equal amounts on a monthly basis. In the event the options do not evenly divide into 24 months, the remaining balance of options granted shall become exercisable on 3/20/2023.